Cost-Effectiveness of Sacituzumab Govitecan and Physician’s Choice of Treatment in Patients with Metastatic Triple Negative Breast Cancer in Spain
Background and Objectives Patients with metastatic triple-negative breast cancer (mTNBC) have poor prognosis and survival outcomes. Sacituzumab govitecan (SG) has shown significant survival benefits, but its cost-effectiveness still needs evaluation. The present study aimed to evaluate the cost-effectiveness of SG versus physician’s choice of treatment in patients with mTNBC in the context of the Spanish…












